Edgewood Oncology reveals encouraging outcomes from a research-driven trial for BTX-A51 in early tests on liposarcoma models.

Alnylam Unveils Encouraging Outcomes from Phase 2 KARDIA-2 Trial with Zilebesiran on Top of Usual Hypertension Medications in Subjects with Poorly Managed High Blood Pressure.

Recent insights reveal that supplementing standard statin treatment with semi-annual doses of Leqvio® (inclisiran) can markedly decrease bad cholesterol levels in individuals with atherosclerotic cardiovascular disease in practical healthcare situations.

Ocugen Reports Encouraging Results and DSMB Assessment, Launches Participant Recruitment for Intermediate Dosage Trial of OCU410, a Genetic Treatment Option, in Early-Stage ArMaDa Research Targeting Geographic Atrophy.

Cidara Therapeutics uses its Cloudbreak technology to develop novel drug-Fc conjugates. The company will showcase four posters at the AACR Annual Meeting.

Adcentrx Therapeutics will showcase early-stage findings of their Nectin-4 antibody-drug conjugate (ADC) initiative at the 2024 AACR Annual Convention.

Carisma Therapeutics reported its Q4 financial results and year-end figures as of December 31, 2023, and provided a corporate update.

The FDA has cleared VOYDEYA™ for use alongside ravulizumab or eculizumab in managing extravascular hemolysis among adult patients with the uncommon disorder PNH.

Vertex Pharmaceuticals Incorporated revealed the progression of inaxaplin (VX-147) to the critical Phase 3 segment of the worldwide Phase 2/3 clinical study focusing on APOL1-related renal conditions.

Asha Therapeutics has revealed its selection of an innovative internal-binding compound, designated ASHA-624, intended as a treatment agent to alter the progression of Amyotrophic Lateral Sclerosis.

The U.S. authorities have endorsed the review of a licensing request for Datopotamab Deruxtecan.

IASO Bio has disclosed official authorization from the China National Medical Products Administration for the clinical trial application of Equecabtagene Autoleucel.